Skip to content

Short-term Outcomes of Laparoscopic Versus Open Gastrectomy With Lymph Node Dissection for Early Gastric Cancer :a Randomized Controlled Study

Short-term Outcomes of Laparoscopic Versus Open Gastrectomy With Lymph Node Dissection for Early Gastric Cancer :a Randomized Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05707338
Enrollment
40
Registered
2023-01-31
Start date
2023-02-28
Completion date
2025-01-31
Last updated
2023-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Gastric Cancer

Brief summary

While the incidence of gastric cancer is gradually declining, it is the fifth most common cancer worldwide and the third most common cause of cancer related death worldwide according to GLOBOCAN 2018 data (Rawla P and Barsouk A.,2019). Laparoscopic distal gastrectomy for early gastric cancer(EGC) was first performed more than 20 years ago (Shi, Y et al.,2018). Laparoscopy-assisted gastrectomy (LAG) for EGC has been confirmed to have oncologic and long-term survival equivalency to the open technique and provide tremendous advantages over open surgery, such as good cosmesis, reduced pain, and shorter hospital stay(Katai H et al.,2017). Based on the experience of EGC, most experienced surgeons have applied the laparoscopic procedure in patients with locally advanced gastric cancer (AGC). Retrospective studies have assessed the technical and oncological safety of LAG with D2 lymph node dissection for AGC(Hao Y et al .,2016). Recently, results of two ongoing randomized controlled trials (RCTs) have revealed the surgical safety of laparoscopic distal gastrectomy with D2 lymphadenectomy for AGC . However, laparoscopic gastrectomy for locally advanced disease remains controversial(Hu Y et al.,2016). Here, we report the short-term surgical outcomes of a RCT comparing laparoscopic and open gastrectomy (OG) with D2 lymph node dissection for EGC, which was designed to assess the technical safety and oncologic feasibility of LAG for EGC.

Detailed description

Aim of the work a prospective randomized controlled trial comparing laparoscopic and open gastrectomy with D2 lymph node dissection for EGC to evaluate technical safety and oncologic feasibility. The postoperative morbidity and mortality rates will be based on the modified intention-to-treat analysis. The aim of this study is to compare the operative and short-term oncologic outcomes of laparoscopic versus open resections. Patients and methods The study design: : prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt. Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group). Study population The study included patients complaining of gastric cancer stage (T1-T2N0M0).The study will start from december 2022 . Inclusion criteria: Inclusion criteria were as follows: histologically confirmed adenocarcinoma of the stomach; pathologically confirmed stage T1-T2; no evidence of distant metastasis by means of abdominal computed tomography(CECT) and CT chest ; D2 lymphadenectomy with curative R0 according to pathological diagnosis after the operation . patients with N1 confirmed pathologically after operation also will be included in the study. The exclusion criteria: 1. pregnancy 2. an American Society of Anesthesiologists (ASA) score \> 3, 3. severe mental disorders 4. prior upper abdominal surgery except laparoscopic cholecystectomy, 5. presence of other malignancies 6. a history of chemotherapy or radiation therapy. 7. unstable angina or myocardial infarction within the past 6 months, severe respiratory disease (forced expiratory volume in 1 s, FEV1 \< 50%) 8. abdominal wall hernia 9. diaphragmatic hernia 10. coagulation disorder 11. portal hypertension 12. Advanced gastric cancer (stage;T3,T4,N1 to 3 ,M1) based on preoperative diagnosis. Approvals and consents This study will be done after obtaining approval from the research ethics committee of the Sohag faculty of medicine. A written Informed consent will be obtained from all participants before being enrolled in the study and before performing the procedure after receiving an explanation of the study protocol, including both types of operation and possible complications. The study will be registered at www.clinicaltrials.gov. Data collection: Registered data will be collected from the hospital databases, clinical data. Randomization Randomization was performed by closed envelopes and was balanced and stratified for proposed type of resection.

Interventions

PROCEDUREGastrectomy with lymph node dissection

prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt. Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group).

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* The study included patients complaining of gastric cancer stage (T1-T2N0M0).The study will start from december 2022 . Inclusion criteria: Inclusion criteria were as follows: histologically confirmed adenocarcinoma of the stomach; pathologically confirmed stage T1-T2; no evidence of distant metastasis by means of abdominal computed tomography(CECT) and CT chest ; D2 lymphadenectomy with curative R0 according to pathological diagnosis after the operation . patients with N1 confirmed pathologically after operation also will be included in the study.

Exclusion criteria

1. pregnancy 2. an American Society of Anesthesiologists (ASA) score \> 3, 3. severe mental disorders 4. prior upper abdominal surgery except laparoscopic cholecystectomy, 5. presence of other malignancies 6. a history of chemotherapy or radiation therapy. 7. unstable angina or myocardial infarction within the past 6 months, severe respiratory disease (forced expiratory volume in 1 s, FEV1 \< 50%) 8. abdominal wall hernia 9. diaphragmatic hernia 10. coagulation disorder 11. portal hypertension 12. Advanced gastric cancer (stage;T3,T4,N1 to 3 ,M1) based on preoperative diagnosis.

Design outcomes

Primary

MeasureTime frame
early postoperative complications20 month

Contacts

Primary Contactmahmoud M Ali, assisstant lecturer
mahmoud.ali@med.sohag.edu.eg01003169674
Backup ContactAbdelhafeez H Mohammad, Professor
01143013313

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026